What's Hot

    Whitecap Resources Exceeds Production Guidance for 2024

    October 26, 2024

    Prospective Future Performance of CNQ Stock: A 5-Year Projection

    October 26, 2024

    Flying Nickel Receives Final Order for Arrangement with Norway House

    October 25, 2024
    Facebook X (Twitter) Instagram
    X (Twitter) RSS
    Micro CapsMicro Caps
    • Featured
    • Sectors
      • Bio Tech & Pharma
      • Economy
      • Industrials & Juniors
      • Mining & Resources
      • Oil, Gas & Energy
      • Technology
      • Cannabis
      • Market
    • Markets
      • Stocks
        • TSX
        • TSXV
        • CSE
    • About Us
      • Contact Us
      • Disclaimer
    Featured
    Micro CapsMicro Caps
    Home»Bio Tech & Pharma»Algernon Pharmaceuticals to present research results on Ifenprodil’s efficacy in treating idiopathic pulmonary fibrosis
    Bio Tech & Pharma

    Algernon Pharmaceuticals to present research results on Ifenprodil’s efficacy in treating idiopathic pulmonary fibrosis

    Alexander LeeBy Alexander LeeAugust 15, 2022Updated:August 16, 2024No Comments2 Mins Read
    Facebook Twitter Pinterest LinkedIn Tumblr Email
    Share
    Facebook Twitter LinkedIn Pinterest Email

    Algernon Pharmaceuticals, a Canadian drug development company in the clinical stage, has announced that they will be presenting the results of their phase 2a study on NP-120 (Ifenprodil) for the treatment of idiopathic pulmonary fibrosis (IPF) and chronic cough at the upcoming American Cough Conference.

    Ifenprodil is an N-methyl-D-aspartate (NMDA) receptor antagonist that targets the NMDA-type subunit 2B (GluN2B), thereby inhibiting glutamate signaling. This innovative treatment represents a first-in-class option for patients with IPF and chronic cough.

    The American Cough Conference serves as a biennial educational platform for healthcare professionals engaged in cough research and management. Dr. Peter Dicpinigaitis, the conference chair, expressed his enthusiasm for Algernon’s findings, stating that he is intrigued by the potential of Ifenprodil in addressing cough related to IPF and refractory chronic cough.

    Algernon specializes in drug re-purposing by exploring the use of approved drugs for new disease indications, with a focus on facilitating their transition to new clinical trials in a safe and efficient manner. Their approach involves developing new formulations and securing regulatory approvals in various global markets.

    Recently, Algernon released additional data from their phase 2a study on Ifenprodil, which demonstrated a significant improvement in reducing patient cough compared to initial reports. A statistical analysis conducted by Dr. Jacky Smith, the company’s lead scientific and medical advisor, revealed notable reductions in mean objective 24-hour and waking cough counts after four and 12 weeks of treatment.

    Christopher Moreau, the CEO of Algernon, commented on the positive implications of the new data, stating that Ifenprodil’s potential as an effective cough treatment has been further validated. He emphasized the importance of exploring its efficacy in patients with chronic cough in the absence of IPF, noting the challenges historically associated with treating cough in IPF patients.

    Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
    Alexander Lee
    • Website

    Alexander is the founder and author of Microcaps.ca, a leading resource for investors interested in the micro-cap stock market. With a passion for uncovering hidden gems in the world of small-cap stocks, Alexander combines in-depth research with years of experience in the financial markets to provide readers with valuable insights and timely analysis. Investors should conduct their own research or consult with a qualified investment advisor before making any investment decisions. The author of this article is not responsible for any gains or losses incurred from investing in companies mentioned.

    Related Posts

    Sona Nanotech Secures Patent and Appoints Board Member

    October 23, 2024

    Cardiol Therapeutics to Proceed with Late-Stage Trial of CardiolRx in Patients Suffering from Recurrent Pericarditis

    October 23, 2024

    Quantum BioPharma Initiates Legal Action Against CIBC World Markets, RBC Dominion Securities, and Other Parties for Alleged Stock Price Manipulation and Spoofing, Seeking Damages Exceeding $700 Million USD

    October 22, 2024

    Leave A Reply Cancel Reply

    Top Posts

    The Global Uranium Boom: How Canada’s Junior Miners Are Positioned to Benefit from the Nuclear Energy Renaissance

    August 28, 202411

    Exploring Opportunities in the Canadian Junior Mining Sector: Key Companies to Watch

    August 19, 202411

    Latin Metals Inc.: Unlocking the Mineral Wealth of Latin America

    August 20, 20249

    GlycoProteMim Highlighted in Stonegate Healthcare’s Most Recent Study on Anti-Aging

    August 19, 20246
    Don't Miss
    Oil, Gas & Energy

    Whitecap Resources Exceeds Production Guidance for 2024

    By Alexander LeeOctober 26, 20240

    Whitecap Resources (TSX:WCP) has released its operating and unaudited financial results for the third quarter…

    Prospective Future Performance of CNQ Stock: A 5-Year Projection

    October 26, 2024

    Flying Nickel Receives Final Order for Arrangement with Norway House

    October 25, 2024

    Graphite One Secures Exclusive Access to Industry-Leading Anode Manufacturing Technology Through Agreements.

    October 25, 2024
    Stay In Touch
    • Facebook
    • Twitter
    • Pinterest
    • Instagram
    • YouTube
    • Vimeo
    About Us
    About Us

    Microcaps.ca delivers timely and insightful Canadian stock market news, focusing on microcap trends, updates, and expert analysis.

    Email: info@microcaps.ca
    Contact: +1 coming soon

    Facebook X (Twitter) Pinterest YouTube WhatsApp
    Our Picks

    Whitecap Resources Exceeds Production Guidance for 2024

    October 26, 2024

    Prospective Future Performance of CNQ Stock: A 5-Year Projection

    October 26, 2024

    Flying Nickel Receives Final Order for Arrangement with Norway House

    October 25, 2024
    Most Popular

    The Global Uranium Boom: How Canada’s Junior Miners Are Positioned to Benefit from the Nuclear Energy Renaissance

    August 28, 202411

    Exploring Opportunities in the Canadian Junior Mining Sector: Key Companies to Watch

    August 19, 202411

    Latin Metals Inc.: Unlocking the Mineral Wealth of Latin America

    August 20, 20249

    Type above and press Enter to search. Press Esc to cancel.

    Go to mobile version